Why BGPT?
logo

Built for bioinformatics workflows

Download raw tables, code snippets, and datasets from full texts to power analyses.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    SHOC2–RAS “targeting” meta-analysis (evidence across papers) — reproducibility-first
    I can’t truthfully quantify “evidence across papers” from the prompt alone (no paper list, effect sizes, or raw results were provided). Below I provide a reproducibility-first meta-analysis workflow you can run once you supply the SHOC2/RAS papers (or let BGPT’s agent fetch them).
    Reproducibility reference frames: risk-of-bias + heterogeneity + reporting checks are standard in systematic reviews/meta-analyses (e.g., ).



     Long Explanation


    Meta-analysis blueprint: “SHOC2–RAS targeting” evidence across papers + reproducibility checks
    Constraint: Your prompt does not include the papers, extracted outcomes, or any raw numbers. I therefore do not compute effect sizes here. Instead, I provide a fully reproducible extraction + meta-analysis plan that the BGPT agent can execute once it retrieves the relevant full-text papers.
    1) What we will define up-front (to avoid hidden assumptions)
    • Index intervention: “SHOC2–RAS targeting” must be operationalized (e.g., genetic SHOC2 perturbation vs biochemical inhibition vs pathway modulation) and restricted to mechanistic claims that match the paper’s data.
    • Comparator: vehicle/untreated, non-targeting control, or alternative pathway perturbation—separately tracked.
    • Outcome hierarchy: pre-specify primary outcomes (e.g., RAS pathway readouts, proliferation, signaling markers) and treat secondary outcomes as exploratory.
    • Study eligibility window: species/cell-system boundaries and whether ex vivo/in vivo/organ-specific evidence is pooled or stratified.
    Method basis for structured systematic review conduct: .
    2) Reproducibility-first evidence pipeline (visual)
    3) Evidence extraction schema (raw data table you should populate)
    Paper Model Intervention operationalization Comparator Outcome (primary/secondary) Effect metric n (per arm) Raw summary stats Assay + timepoint Notes for bias
    No papers were provided in your message; BGPT agent will fill this after retrieval.
    4) Meta-analysis plan + reproducibility checks (what will be computed)
    • Model: random-effects synthesis is typically used when studies differ (species/models/assays), but the exact choice will be justified after heterogeneity is assessed.
    • Heterogeneity: quantify inconsistency and inspect whether stratification (e.g., in vitro vs in vivo) changes conclusions.
    • Sensitivity analyses: remove high-risk-of-bias studies; re-run with alternative outcome definitions; check influence of single studies.
    • Publication/reporting bias checks: where enough studies exist, assess asymmetry and compare selective reporting signals.
    Method basis for heterogeneity-aware meta-analysis and systematic review practices: .
    5) Results visualization templates (ready once raw effects are extracted)
    6) Blind spots & common failure modes (what we will explicitly test)
    • Outcome ambiguity: “targeting” can mean direct SHOC2 inhibition or indirect RAS-pathway modulation; mixing them can fake consistency.
    • Model confounding: pooling across cell lines/species without stratification can invert conclusions.
    • Non-independence: multiple assays per paper may not be independent; extraction must track clustering.
    • Selective reporting: if key timepoints/metrics are missing, effect estimates become fragile.
    These are generic systematic-review risks; Cochrane’s handbook provides the methodological scaffold for addressing them through bias assessment and sensitivity analyses.


    Feedback:    

    Updated: April 30, 2026

     Analysis Wizard



    It will import BGPT-extracted raw per-arm results for SHOC2–RAS targeting papers, compute effect sizes with uncertainty, then generate forest/funnel and sensitivity stratifications directly from the extracted tables.



     Hypothesis Graveyard


    Assuming all “RAS downregulation” readouts across different assays are equivalent will likely collapse effect sizes into misleading averages; definitional mismatch is a more plausible explanation than true uniform biology.


    Pooling in vitro and in vivo without stratification will not “average out” model differences; it will typically inflate heterogeneity and make sensitivity conclusions unstable.

     Science Art


    Meta-analysis: SHOC2–RAS targeting evidence across papers reproducibility checks Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending